Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases

Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases is a phase 2/3, randomised interventional study registered as NCT02758951 by Koen Rovers, with a registry enrolment figure of 358 participants, started 2017-06-01 and due to reach its primary completion in 2024-10-31. Interventions recorded: Perioperative systemic therapy; Perioperative CAPOX-bevacizumab; Perioperative FOLFOX-bevacizumab; Perioperative FOLFIRI-bevacizumab; CRS-HIPEC, experimental arm; CRS-HIPEC, control arm. Conditions listed: Colorectal Neoplasm; Colorectal Cancer; Colorectal Neoplasms Malignant; Colorectal Carcinoma; Colorectal Adenocarcinoma; Peritoneal Neoplasms; Peritoneal Carcinomatosis; Peritoneal Cancer; Peritoneal Metastases; Peritoneal Neoplasm Malignant Secondary Carcinomatosis; Peritoneal Neoplasm Malignant Secondary. Primary outcome: Overall survival. Colorectal eligibility wording from the registry: "* histological or cytological proof of PM of a non-appendiceal colorectal adenocarcinoma with ≤50% of the tumour cells being signet ring cells;". Sites: Belgium, Netherlands. No results are recorded here; the registry entry is the source.